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Abstract
Background: Several glitazones (PPARc agonists) and glitazars (dual PPARa/c agonists) have been developed to treat
hyperglycemia and, simultaneously, hyperglycemia and dyslipidemia, respectively. However, most have caused idiosyncratic
hepatic or extrahepatic toxicities through mechanisms that remain largely unknown. Since the liver plays a key role in lipid
metabolism, we analyzed changes in gene expression profiles induced by these two types of PPAR agonists in human
hepatocytes.
Methodology/Principal Findings: Primary human hepatocytes and the well-differentiated human hepatoma HepaRG cells
were exposed to different concentrations of two PPARc (troglitazone and rosiglitazone) and two PPARa/c (muraglitazar and
tesaglitazar) agonists for 24 h and their transcriptomes were analyzed using human pangenomic Agilent microarrays.
Principal Component Analysis, hierarchical clustering and Ingenuity Pathway AnalysisH revealed large inter-individual
variability in the response of the human hepatocyte populations to the different compounds. Many genes involved in lipid,
carbohydrate, xenobiotic and cholesterol metabolism, as well as inflammation and immunity, were regulated by both
PPARc and PPARa/c agonists in at least a number of human hepatocyte populations and/or HepaRG cells. Only a few genes
were selectively deregulated by glitazars when compared to glitazones, indicating that PPARc and PPARa/c agonists share
most of their target genes. Moreover, some target genes thought to be regulated only in mouse or to be expressed in
Kupffer cells were also found to be responsive in human hepatocytes and HepaRG cells.
Conclusions/Significance: This first comprehensive analysis of gene regulation by PPARc and PPARa/c agonists favor the
conclusion that glitazones and glitazars share most of their target genes and induce large differential changes in gene
profiles in human hepatocytes depending on hepatocyte donor, the compound class and/or individual compound, thereby
supporting the occurrence of idiosyncratic toxicity in some patients.
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Introduction
Peroxisome proliferator-activated receptors (PPARs) are an
important class of ligand-activated transcription factors involved in
the regulation of nutrient homeostasis, as well as a variety of other
biological processes [1]. This superfamily of nuclear receptors
comprises 3 subtypes: PPARa, PPARb/d and PPARc, also known
as NR1C1, NR1C2 and NR1C3, respectively [2]. Synthetic drugs
activating PPARa and PPARc are in clinical use: the former
typified by fibrates, are used to treat dyslipidemia, while the latter
include glitazones that act as insulin sensitizers in type 2 diabetes
mellitus [3]. First generation of glitazones were found to be highly
hepatotoxic: the first one, ciglitazone, was abandoned after clinical
trials and the second, troglitazone (TRO), was rapidly withdrawn
from the market after reports of severe liver failure and death [4].
By contrast, the second generation of glitazones developed as
PPARc agonists, namely rosiglitazone (ROSI) and pioglitazone,
have been shown to cause much less frequent and severe
hepatotoxicity. Dual PPARa and PPARc agonists have also been
developed by the pharmaceutical industry for the simultaneous
treatment of hyperglycemia and dyslipidemia, but the first
developed drugs, muraglitazar (MURA) and tesaglitazar (TESA),
were terminated during clinical trials due to cardiac and renal
side-effects, despite the absence of noticeable hepatic lesions [5].
The mechanisms of these idiosyncratic toxicities of glitazones and
glitazars in humans remain unclear.
Major species-differences have been observed in liver sensitivity
to PPAR agonists as first witnessed with fibrates, which have safely
been used for years to lower plasma triglycerides in humans,
whereas in rodents they induced various hepatic lesions, including
increased peroxisome proliferation in addition to hepatic hyper-
trophy and hyperplasia that ultimately result in liver tumors [6,7].
Preclinical animal studies did not predict glitazone hepatotoxicity
or glitazar cardiac and renal toxicities in humans. Therefore, it
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might be postulated that both glitazones and glitazars regulate
different sets of genes in humans and rodents. Consequently,
human liver cell models should represent a more appropriate
approach than their rodent counterparts for investigations of the
hepatotoxic effects of PPAR agonists. In spite of limitations due to
scarce availability, interindividual variability and short-term in vitro
life-span that does not allow the study of long term effects of
chemicals, primary human hepatocyte cultures are recognized as
the most appropriate in vitro system for investigations of drug-
induced hepatic effects [8].
To our knowledge, a comprehensive analysis of gene regulation
by PPARc and PPARa/c agonists in human hepatocytes has not
been published. The aim of the present study was to identify
changes in gene expression profiles induced by PPARc and
PPARa/c agonists in human hepatocytes from several donors and
in differentiated human hepatoma HepaRG cells using a whole
genome transcriptomic approach. The HepaRG cell line repre-
sents a potentially suitable surrogate to primary hepatocytes since
it combines the advantages of the expression of most of the liver-
specific functions, including the major cytochromes P450 at levels
comparable to those found in primary human hepatocytes and the
relative functional stability for several weeks at confluence [9,10].
Large inter-individual variations in gene expression profiles
were highlighted in response to 24 h treatments with different
PPARc and PPARa/c agonists. However, in addition to many
common altered genes that have also frequently been identified as
PPARa target genes, small subsets of genes were found to be
restricted to either individual or one class of test agonists.
Materials and Methods
Chemicals
Williams’ E medium was supplied by Eurobio (Les Ulis, France)
and fetal calf serum (FCS) by Perbio (Brebieres, France). TRO,
ROSI, MURA and TESA were synthesized by the Servier
Chemical Department. [3H(G)]Taurocholic acid (sp. Act. 1.19 Ci/
mmol) was purchased from Perkin-Elmer Life Science (Boston,
MA) and dichlorofluorescein diacetate (DCFDA) was purchased
from Invitrogen (Cergy Pontoise, France). All other chemicals
were of the highest quality available.
Primary human hepatocytes (PHH)
Human hepatocytes from four adult donors undergoing resection
for primary and secondary tumors were obtained by collagenase
perfusion of histologically normal liver fragments [11] (Table S1).
They were seeded at a density of 176104 cells/cm2 in 6-well dishes
in a Williams E medium supplemented with 10% fetal calf serum
(FCS), 100 units/mL penicillin, 100 mg/mL streptomycin, 1 mg/mL
insulin, 2 mM glutamine and 1 mg/mL bovine serum albumin. The
medium was discarded 12 h after seeding and cells were thereafter
maintained in serum-free medium supplemented with 1027 M
hydrocortisone hemisuccinate.
HepaRG cells
The HepaRG cell line is derived from a liver tumor of a female
patient [12]. For the present studies, HepaRG cells were first
seeded at a density of 2.66104 cells/cm2 in 6-well dishes in a
Williams’ E medium supplemented with 10% FCS, 100 units/mL
penicillin, 100 mg/mL streptomycin, 5 mg/mL insulin, 2 mM
glutamine and 561025 M hydrocortisone hemisuccinate. After
two weeks of culture, they were shifted to the same culture
medium supplemented with 2% dimethylsulfoxide (DMSO) for
two further weeks in order to reach maximum functional activities.
Media were renewed every 2–3 days. Differentiated HepaRG cell
cultures are composed of both hepatocyte-like and biliary-like cells
(about 50% of each type) [13].
PPAR agonist treatments
TRO, ROSI, MURA and TESA were dissolved in DMSO and
stored frozen at a concentration of 300 mM until use. HepaRG
cell cultures were exposed to varying concentrations of each
compound for 24 h in FCS- and DMSO-free medium. Primary
human hepatocytes were cultured for 24 h before exposure to the
same concentrations of PPAR ligands.
ATP assay
An ATP assay was used to estimate cell viability. ATP content
was assayed in 96-well culture plates after 24 h exposure to 0, 5,
20, 40 mM of TRO; 0, 50, 100, 150 mM of ROSI and MURA and
0, 200, 300 and 2000 mM of TESA. At the end of the incubation
period, cultures were observed under phase-contrast microscopy
using an Olympus 1670 microscope. Intracellular ATP content
was measured using the Cell Titer-Glo Luminescent Cell Viability
Assay kit (Promega, Charbonnie`res, France). ATP determinations
were performed at least in triplicate. Results were normalized to
control cells and expressed as mean 6 SD.
Measurement of caspase 3-like activity
After a 24 h treatment by PPAR agonists, differentiated HepaRG
cells were harvested in the treatment medium and stored as pellets
at 2 80uC. After cell lysis, 40 mg of proteins were incubated with
80 mM Ac-DEVD-AMC in caspase-3 activity buffer (20 mM
PIPES pH 7.2, 100 mMNaCl, 10 mM dithiotreitol, 1 mMEDTA,
0.1% CHAPS and 10% sucrose) at 37uC for 1 h. Caspase 3-
mediated cleavage of Ac-DEVD-AMC peptide was continuously
measured by spectrofluorimetry using excitation/emission wave-
lengths of 380/440 nm. The data were normalized to control
values, and the control was expressed as a value of 100%.
Determination of Reactive Oxygen Species (ROS)
production
Cells were incubated in the dark at 37uC for 2 h with 0.33 mM
DCFDA in culture medium. At the end of the incubation period,
300 ml of 5 ml of 200 mMK2HPO4/KH2PO4, 5 ml methanol and
10 ml triton X100 were added. The rate at which ROS formed the
fluorescent product was measured with a microplate reader using
excitation/emission wavelengths of 485/530 nm. The data were
normalized to control values, and the control was expressed as a
value of 100%.
Western blotting
Fifty mg of total cellular protein extracts were resolved on 7.5%
SDS–PAGE, transferred onto nitrocellulose membranes (Milli-
pore, Guyancourt, France) and analyzed using chemiluminescence
detection. The following antibodies were used: rabbit anti-human
PPARc (sc-29455, Santa Cruz biotechnology, Tebu, France) and
mouse anti-human Heat Shock Cognate 70 (HSC70) (B-6, sc-
7298, Santa Cruz Biotechnology, Tebu, France).
RNA isolation
Cells were harvested in lysis buffer (RLT buffer and b-
mercaptoethanol). Total RNA was isolated using the RNeasy
mini Kit (Qiagen, Venlo, Netherlands). RNA quantity and
purity were assessed with a Nanodrop ND-1000 spectropho-
tometer (Nyxor Biotech, Paris, France) and RNA integrity was
checked on a Bioanalyzer 2100 (Agilent Technologies, Massy,
France).
PPARc Target Genes in Human Liver
PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e18816
Microarray hybridizations
Five hundred ng of total RNA from each control and PPAR
agonist-treated cell culture were separately reverse-transcribed
into double-strand cDNA by the Moloney murine leukaemia virus
reverse transcriptase and amplified for 2 h at 40uC using Quick
Amplification Labeling Kit (Agilent). The cDNA was then
transcribed into antisense cRNA and labelled with either CTP-
Cy3 or CTP-Cy5 fluorescent dyes for 2 h at 40uC following the
manufacturer’s protocol. Cyanine-labeled cRNAs were purified
using RNeasy minikit (Qiagen). The cRNAs of both control and
PPAR-treated HepaRG cells or PHH were hybridized on Agilent
Gene chip human genome Microarrays (G4112F) according to
standard Agilent protocols. Human hepatocyte and HepaRG cell
samples were hybridized separately. Data analyses were performed
using Rosetta Resolver v.7.0 software (Rosetta Biosoftware,
Seattle, WA) for database management, quality control and
analysis. All microarray data reported in this study complied with
MIAME guidelines [14].
qPCR analysis
Transcripts of some genes were also estimated by quantitative
PCR in order to confirm microarrays results. Briefly, 500 ng of
total RNA was reverse-transcribed into cDNA using the High-
Capacity cDNA Archive kit (Applied Biosystems, Foster City,
CA). qPCR was performed by the fluorescent dye SYBR Green
methodology using the SYBR Green PCR Master Mix (Applied
Biosystems) and the STEP one Plus (Applied Biosystems). Primer
pairs for each transcript were chosen with qPrimer depot software
(http://primerdepot.nci.nih.gov/) (Table S2). Amplification
curves were read with the StepOne software V2.1 using the
comparative cycle threshold method. The relative quantification
of the steady-state mRNA levels was normalized against 18S
mRNA.
Sodium-taurocholate cotransporting polypeptide (NTCP)
transport assays
Activity of the NTCP transporter was estimated by measuring
sodium-dependent intracellular accumulation of radiolabeled
taurocholate substrate as previously described [15]. Briefly, cells
were incubated at 37uC for 30 min with 0.17 mM [3H]tauro-
cholate in the presence or absence of sodium. After washing
with phosphate-buffered saline, cells were lysed in 0.1 N NaOH,
and accumulation of radiolabeled substrates was determined
through scintillation counting. Taurocholate accumulation
values in the presence minus absence of sodium represented
NTCP activity.
Statistical analysis
Normalization algorithms and background subtractions were
automatically applied to each array to reduce systematic errors
and to adjust effects due to technological rather than biological
variations using Feature ExtractionH and ResolverH software.
Thereby, significantly modulated genes (at the Entrez Gene
level) were analyzed according to a p-value #0.01 and a 1.5-fold
change as filters. Principal component analysis (PCA) and
hierarchical clustering were performed to visualize behaviour
of data through cell models, products and concentrations.
Biological functions and pathways were generated and analyzed
using Ingenuity Pathway AnalysisH v.7.0 (IPA, Ingenuity System,
CA) from all data and relevant gene-sets. The Mann and
Whitney test was used for statistical analysis of ATP, ROS,
caspase 3 activity, PPARc protein expression and NTCP activity
values.
Results
Cytotoxic effects of PPAR agonists
Preliminary experiments were carried out to estimate the
concentrations at which the four compounds caused cellular
damage in primary human hepatocytes and HepaRG cells after a
24 h exposure, using the intracellular ATP content assay. TRO
was ineffective at 5 and 20 mM in both cell models while at 40 mM
it caused a greater decrease in ATP content in HepaRG cells, the
values dropping to 53619% (Figure 1). ROSI and MURA caused
intracellular ATP changes from 150 mM, and TESA did not cause
any effect, except a slight decrease at 2000 mM, in HepaRG cells.
Examination of cell cultures at the end of the treatment time under
phase-contrast microscopy revealed morphological alterations only
in cultures exhibiting a significant decrease in ATP content. Toxic
effects at the highest concentrations of TRO and MURA were
confirmed by measuring caspase 3 activity (Figure 2) and an
increase in ROS production was demonstrated by DCFDA
quantification in HepaRG cells (Figure 3). 50 mM MURA,
100 mM MURA and 20 mM TRO induced a slightly but
significantly increase of ROS production, caspase 3 activity and
both respectively.
mRNA basal expression of PPARa and PPARc was also
measured by qPCR in freshly isolated human hepatocytes and in
PHH and HepaRG cell cultures (Figure 4). No significant
differences were observed in the three cell types. As expected,
PPARa transcripts were found to be at least 3-fold more abundant
than PPARc transcripts. No expression of PPARc2 was detected
in any cell type (data not shown). Moreover, the comparable
amount of PPARc transcripts in the two cell culture models was
confirmed at the protein level by western blotting analysis
(Figure 5).
Based on all these initial data, a low, medium and subtoxic
concentrations of TRO, ROSI and MURA were further selected
for microarray analysis. Because of the absence of any cytotoxicity
with TESA, even at 2000 mM, only one concentration of this
PPAR agonist was studied.
Numbers of deregulated genes
The numbers of total modulated genes, as well as the up- and
down regulated genes in PHH and HepaRG cell cultures treated
with each of the four compounds are displayed in Table 1. The
numbers of modulated genes greatly varied depending on the
hepatocyte donor, with a concentration-related effect in both cell
models irrespective of the tested compound. Marked individual
differences were seen in response to the PPAR agonists between
the four human hepatocyte donors. Differences in gene expression
with ROSI and MURA reached about 4 to 5-fold between the 4
donors at the low concentrations while they were only about 2-fold
at high concentrations. Thus, at the lowest concentration tested,
TRO modulated 428 to 2910 genes, ROSI 716 to 3135 genes,
MURA 1642 to 3089 genes and TESA 2111 to 3277 genes. The
lowest and the highest numbers of deregulated genes for each
PPAR agonist were obtained in hepatocyte cultures from different
donors. The lowest numbers of modulated genes with TRO,
ROSI, MURA and TESA were observed with donors#3,#1,#2
and #2 respectively. The respective percentages of up- and down-
regulated genes generally ranged between 40 and 60% although
some exceptions were noticed: thus the percentages of down-
regulated genes reached around 75% for donor #3 treated with
the low concentrations of ROSI and MURA. Much less variations
in the number of deregulated genes, not exceeding 2-fold, were
observed between the three passages of HepaRG cells. The
percentages of down-regulated genes reached around 60% of total
PPARc Target Genes in Human Liver
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deregulated genes with low concentrations of ROSI and MURA
and 300 mM TESA, whereas they represented only around 30%
with 5 mM TRO.
Using the Rosetta resolverH software, data from each donor
were combined to be representative of a virtual pool of the 4
hepatocyte populations treated with the different PPAR agonists.
In such a situation the total numbers of deregulated genes, as well
as the numbers of up- and down-regulated genes, were greatly
reduced, although a concentration-related effect was still observed
whatever the tested compound. The total number of modulated
genes did not exceed 1000 genes in the combined human
hepatocyte donors, except with 150 mM ROSI (2735 genes) and
100 and 150 mM MURA (approximately between 1500 and 5000
genes). The combined values of the three HepaRG cells passages
were usually greater than 1000 genes with 40 mM TRO, and 100
and 150 mM ROSI and MURA.
Hierarchical clustering
Clustering using both the Euclidian and the Pearson distances
associated to the ward’s min variance link heuristic criteria were
used on combined data. The first dendrogram showed the
unspecific toxic signatures with the highest concentration of
MURA and ROSI in both cell models, while the second clustering
allowed a clear separation between glitazones and glitazars in
human hepatocytes. The same conclusions were obtained with
HepaRG cells except with 20 mM MURA which was closed to 5
and 20 mM of TRO, likely because the low number of modulated
genes (data not shown).
Two-dimensional hierarchical clustering of gene expression
from human hepatocytes and HepaRG cells treated with either
glitazones or glitazars was also performed (Figure 6). Two main
clusters were demonstrated with both glitazones and glitazars. One
branch grouped all hepatocyte 150 mM ROSI treatments and 50
or 100 mM ROSI treatments from donor #2. The second branch
grouped all other treatments and was divided into 4 subtrees.
Naturally, glitazone treatments were clustered more closely by
donors than by treatment. After TRO treatment, donors #3 and
#4 were closer to HepaRG cells than donors #1 and #2.
With glitazars, one of the two main branches grouped all 150 mM
MURA treatments, except for donor#2. The other branch diverged
into two distinct subtrees: one grouped all other HepaRG cell
treatments and hepatocytes from donor #1 treated with 50 mM
MURA and hepatocytes from donors#1 and#2 treated with TESA
indicating that donors #1 and #2 were more similar to HepaRG
cells than donors #3 and #4 under these treatment conditions.
Functional analysis
Ingenuity pathway analysis was conducted on whole gene
expression profiles in order to characterize the canonical pathways
and biological and toxicological functions responsive to the four
compounds at the different concentrations tested. Whatever the
treatment and the cell model, these included ‘‘Fatty Acid (FA)
Figure 1. Intracellular ATP content in primary human hepatocytes and HepaRG cells treated with PPARc or PPARa/c agonists.
Intracellular ATP content was measured in cells treated with TRO, ROSI, MURA or TESA for 24 h. Results are normalized to control cells and expressed
as means 6 S.D. of three independent experiments.* p,0.05, N.T.: non tested.
doi:10.1371/journal.pone.0018816.g001
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metabolism’’, ‘‘LPS/IL1 mediated inhibition of RXR function’’
and ‘‘Metabolism of xenobiotics’’. In addition ‘‘Hepatic cholesta-
sis’’ was identified with TRO treatment and ‘‘Bile acid
metabolism’’ with the other three PPAR agonists. Finally,
‘‘PXR/RXR activation’’ was also identified with the two
glitazones and ‘‘LXR/RXR activation’’ with the two glitazars.
Figure 2. Caspase 3 activity in HepaRG cells treated with PPARc or PPARa/c agonists. Caspase 3 levels were determined in HepaRG cells
after a 24 h treatment with TRO, ROSI, MURA or TESA. Staurosporine (2 mM) was used as a positive control. Results are normalized to control cells and
expressed as means 6 S.D. of three independent experiments.* p,0.05.
doi:10.1371/journal.pone.0018816.g002
Figure 3. ROS levels in HepaRG cells treated by PPARc or PPARa/c agonists. ROS levels were estimated by measurement of intracellular
DCFDA in HepaRG cells after a 24 h treatment by TRO, ROSI, MURA or TESA. Menadione (2 mM) was used as a positive control. Results are normalized
to control cells and expressed as means 6 S.D. of three independent experiments.* p,0.05.
doi:10.1371/journal.pone.0018816.g003
PPARc Target Genes in Human Liver
PLoS ONE | www.plosone.org 5 April 2011 | Volume 6 | Issue 4 | e18816
Gene expression analysis
The numbers of commonly modulated genes in the 4 human
hepatocyte donors varied from 9 to 71% depending on PPAR
agonist and concentration (Table 2). With respect to the total
number of deregulated genes, these percentages ranged from 9 to
62%, 17 to 71%, 27 to 51u% and 31 to 48% with 5 mM TRO,
50 mM ROSI, 50 mM MURA and 300 mM TESA, respectively.
By comparison, in the 3 HepaRG cell passages, these
percentages ranged from 39 to 53%, 41 to 70%, 44 to 61%
and 52 and 55% with 5 mM TRO, 50 mM ROSI, 50 mM
MURA and 300 mM TESA, respectively. Accordingly, the
calculated mean correlation coefficients were much lower
between the hepatocyte donors than between the 3 HepaRG
cell passages (Table 2). The percentages of commonly deregu-
Figure 4. PPARa and PPARc1 transcript levels in freshly isolated hepatocytes, primary human hepatocytes and HepaRG cells.
Comparative expression of PPARa and PPARc1 in freshly isolated hepatocytes (FIH), primary human hepatocytes (PHH) and differentiated HepaRG
cells incubated in a medium containing 0.01% DMSO. The results are expressed relative to 18S and are the mean 6 S.D.of at least three independent
experiments.
doi:10.1371/journal.pone.0018816.g004
Figure 5. PPARc protein level in primary human hepatocytes and HepaRG cells. Primary human hepatocytes and differentiated HepaRG
cells were incubated in a medium containing 0.01% DMSO. The results are expressed as optical density per 100 mg total protein and are the mean 6
S.D. of at least three independent experiments. ns, not statistically significant.
doi:10.1371/journal.pone.0018816.g005
PPARc Target Genes in Human Liver
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Table 1. Up- and down-regulated genes by PPAR agonists in primary human hepatocytes and HepaRG cells.
Compound
(mM) Primary human hepatocytes HepaRG cells
Donor Total genes Up-regulated
Down-
regulated Passage Total genes Up-regulated
Down-
regulated
TRO
(5)
1 2174 1295 879 9 182 116 66
2 2910 1682 1228 10 144 94 50
3 428 234 194 11 197 130 67
4 872 315 557
combined data 174 111 63 combined data 152 109 43
TRO
(20)
1 4281 2274 2007 9 335 208 127
2 2763 1518 1245 10 328 160 168
3 835 649 186 11 560 308 252
4 1180 451 729
combined data 276 158 118 combined data 391 230 161
TRO
(40)
3 1640 1113 527 9 1242 635 607
4 1142 453 689 10 1579 883 696
11 1056 546 510
combined data 458 220 238 combined data 1314 733 581
ROSI
(50)
1 716 327 389 9 1169 545 624
2 3135 1396 1739 10 1282 607 675
3 1160 419 741 11 781 355 426
4 747 349 398
combined data 240 121 119 combined data 938 453 485
ROSI
(100)
1 870 349 521 9 3240 1473 1767
2 4408 2014 2394 10 3761 1730 2031
3 2165 786 1379 11 2128 953 1175
4 2104 863 1241
combined data 303 124 179 combined data 2868 1295 1573
ROSI
(150)
1 4215 2196 2019 9 7104 3234 3870
2 5527 2546 2981 10 6954 3162 3792
3 2871 1416 1455 11 6619 3264 3355
4 5274 2485 2789
combined data 2735 1390 1345 combined data 6855 3166 3689
MURA
(50)
1 1950 886 1064 9 1134 448 686
2 1642 858 784 10 1040 550 490
3 2678 867 1811 11 825 371 454
4 3089 1171 1918
combined data 597 240 240 combined data 744 328 416
MURA
(100)
1 4061 1845 2216 9 2924 1221 1703
2 2405 1002 1403 10 2880 1180 1700
3 4224 1683 2541 11 1952 641 1311
4 4490 1702 2788
combined data 1473 575 898 combined data 2363 903 1460
MURA
(150)
1 7834 3832 4002 9 7662 3628 4034
2 4933 2156 2777 10 7189 2996 4193
PPARc Target Genes in Human Liver
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lated genes and the mean correlation coefficients increased with
compound concentrations. Interestingly, these percentages were
as low as 0.3, 2.5, 2.5 and 2.5% in the 4 human hepatocytes and
13.4, 24.4, 17.6 and 16.3% in the 3 HepaRG cell passages
treated with 5 mM TRO, 50 mM ROSI, 50 mM MURA and
300 mM TESA, respectively (Table 3).
Venn diagrams were performed on the differentially expressed
genes in the PHH and HepaRG cells treated with the four agonists
Figure 6. Two-dimensional hierarchical clustering of gene expression profiles in hepatocytes treated with PPAR agonists. The
clustering was generated by using Resolver system software with an agglomerative algorithm Ward’s min variance link heuristic criteria and Euclidean
distance metric (FC$1.5 and p#0.01). Two-dimensional clustering was performed on gene expression profiles in hepatocytes treated with glitazones
(a) and glitazars (b).
doi:10.1371/journal.pone.0018816.g006
Compound
(mM) Primary human hepatocytes HepaRG cells
Donor Total genes Up-regulated
Down-
regulated Passage Total genes Up-regulated
Down-
regulated
3 8194 4032 4162 11 7541 3516 4025
4 8637 4134 4503
combined data 5004 2489 2515 combined data 7552 3510 4042
TESA
(300)
1 2906 1177 1729 9 858 408 450
2 2111 980 1131 10 902 335 567
3 3277 1294 1983 11 874 429 445
4 2479 862 1617
combined data 570 223 347 combined data 839 395 444
Genes were taken as differentially expressed when at least 1.5-fold change with p#0.01.
doi:10.1371/journal.pone.0018816.t001
Table 1. Cont.
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at different concentrations (Figure 7). In PHH, 123 deregulated
genes were identified in PPARc and PPARa/c agonist treatments,
while 98 and 458 deregulated genes were restricted to glitazones
and glitazars, respectively. In the different HepaRG cell passages,
127 genes were common between PPARc and PPARa/c agonists,
and 89 and 205 were restricted to glitazones and glitazars,
respectively. By contrast, in both cell models, only a small set of 14
genes was identified as being deregulated in common by both
glitazones and glitazars, while only 11 and 60 genes were
deregulated in common by glitazones and glitazars, respectively.
The 14 commonly altered genes by all PPAR agonists in both cell
models included genes implicated in lipid metabolism (CD36,
PLIN4, ADFP, ANGPTL4) and oxidative stress (POR, HMOX1).
The 11 genes modulated only by the two glitazones in both culture
models were involved in two main functions, namely, xenobiotic
metabolism (CYP3A4, CYP3A7, ADH1B) and the immune
system (CD14). As anticipated among the 60 genes deregulated
only by glitazars, many were known as PPARa target genes
(ACSL1, ACSL5, CPT1A, FGF21); other modulated genes were
involved in calcium homeostasis (CD52, CC7) and cell-cell
signalling (KCND2, CCR1, CXCL13).
However, many more deregulated genes were identified when
only one cell model, an individual human hepatocyte population,
a class of agonists or an individual agonist was specifically
considered. However, whatever the condition, a majority of the
altered genes were involved in various aspects of lipid metabolism,
as well as other functions, including glucose, cholesterol and bile
acids and amino acid metabolisms, chemical biotransformation,
Table 2. Percentages of common modulated genes and correlation coefficients between donors in primary human hepatocytes
and passages in HepaRG cells.
Compound Concentration (mM) Primary human hepatocytes HepaRG cells
common modulated
genes (%)
Mean correlation
coefficients
between donors
common modulated genes
(%)
Mean correlation
coefficients
between passages
donor number passage number
1 2 3 4 9 10 11
TRO 5 46.0 61.6 9.1 18.5 0.25 48.9 38.7 53.0 0.69
20 68.2 44.0 13.3 18.8 0.27 40.7 39.8 68.0 0.68
ROSI 50 16.3 71.4 26.4 17.0 0.47 61.1 70.0 40.9 0.75
100 12.6 63.8 31.3 30.4 0.47 67.2 78.1 44.2 0.82
150 45.2 59.2 30.2 56.5 0.64 73.7 72.1 68.6 0.82
MURA 50 32.1 27.0 44.1 50.9 0.38 60.9 55.8 44.3 0.66
100 47.9 28.4 49.9 53.0 0.56 71.3 70.2 47.6 0.78
150 58.8 37.0 61.5 64.8 0.62 79.8 74.8 78.5 0.89
TESA 300 42.5 30.9 48.0 36.3 0.26 52.1 54.8 53.1 0.62
Percentages of common genes modulated in human hepatocytes from each donor or each HepaRG cells passage and correlation coefficients (FC$1.5 and p#0.01).
doi:10.1371/journal.pone.0018816.t002
Table 3. Percentages of responsive genes modulated by PPAR agonists in primary human hepatocytes and in HepaRG cells.
Compound Concentration (mM) Common modulated genes (%)
Primary human hepatocytes HepaRG cells
Number of donors Number of passages
1 2 3 4 1 2 3
TRO 5 100.0 30.4 4.2 0.3 100.0 27.1 13.4
20 100.0 37.6 5.9 0.8 100.0 33.4 14.7
40 100.0 56.2 31.3
ROSI 50 100.0 21.2 7.2 2.5 100.0 44.4 24.4
100 100.0 39.8 16.4 5.4 100.0 57.4 32.0
150 100.0 52.4 27.7 11.4 100.0 68.4 45.9
MURA 50 100.0 33.8 9.5 2.5 100.0 36.5 17.6
100 100.0 45.9 20.3 6.0 100.0 53.9 30.1
150 100.0 64.8 37.2 14.3 100.0 75.8 58.7
TESA 300 100.0 37.7 9.2 2.5 100.0 36.2 16.3
Percentages of responsive genes modulated by PPAR agonists in primary human hepatocytes from one to four donors and in one to three passages of HepaRG cells.
doi:10.1371/journal.pone.0018816.t003
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inflammation or immunity (Table 4). Several genes were
specifically altered by glitazone treatment in one liver cell model
only. Thus, in PHH, glitazone treatment affected expression of
some genes involved in either xenobiotic metabolism (CYP2C8) or
bile acid transport (SLCO1B3 also called OATP-8), while other
genes were deregulated by only one of the 2 glitazones tested, (i.e.
UCP2 by TRO and ALDH3A1, CYP1A2 and SLC10A2 by
ROSI). Among the modulated genes restricted to HepaRG cells,
AKR1B1 and AKR1B10 were deregulated by both glitazones,
while ABCD3 and PCK1 were altered by TRO only and GPD2,
HADHA, AKR1C3 and PC by ROSI only.
In PHH, glitazars caused deregulation of several genes involved
in either lipid metabolism (ACADVL and ACAA2) or glucose
homeostasis (GK). In addition, FADS1 and ACOX1, were
induced by MURA and TESA respectively. In HepaRG cells,
while PCK1 was modulated by both glitazars, ACADL and
PNPLA2 deregulation was restricted to MURA and ACADS to
TESA. Finally, some genes were found up-regulated by all PPAR
agonists only in either PHH (HMGCS2, CCL3) or HepaRG cells
(LIPE, IL1b, MGST3, CRP).
Additionally, both qualitative and quantitative differences were
observed with several genes in response to the four compounds in
the two cell models. Large variations in their extent of modulation
were also observed with several genes in response to the four
compounds. Thus, in HepaRG cells, changes in ADFP, FABP4 or
ANGPTL4 expression induced by TRO, ROSI and MURA at
equimolar concentrations (i.e. 20 mM) ranged between 2- and 5-
fold. Similarly, huge interdonor variations were demonstrated in
many responsive genes and several target genes were deregulated
only in some donors. Thus, induction of FABP4 varied 3-fold and
13-fold among the donors treated with 20 mM TRO and 50 mM
MURA, respectively. Similar variations were observed with some
down-regulated genes. As an example, an 8-fold difference was
observed in CYP7A1 down-regulation between the 4 donors after
a 20 mM TRO treatment (Tables S3 and S4). Opposite regulation
was also observed with a few genes between the donors, as, for
example, for PDK4, which was up-regulated in donors#1 and#2
but down-regulated in donors #3 and #4 after treatment with
5 mM and 20 mM TRO. These results were confirmed by qPCR
analysis (data not shown).
Comparative microarray and qPCR data
Microarray and qPCR results were compared for several genes
at the lowest concentration of each PPAR agonist and, in addition,
at the middle concentration of TRO in HepaRG cells (Table 5).
For each analysis the direction of change obtained by q-PCR was
similar to that observed with microarrays and, as usually seen,
qPCR values were often higher. As expected, transcripts encoding
FABP4, PDK4, FABP1, ADFP and CYP3A4 were greater after
treatment with the four PPAR agonists, while those of CYP2B6
increased only with the two glitazones. Expression of two genes
representative of liver-specific functions, namely albumin and
aldolase B, was not affected by any of the treatments, except for a
slight increase in aldolase B with 300 mM TESA. PPARa
expression was slightly induced by MURA while PPARc
expression was increased by 5 mM TRO and decreased by both
MURA and TESA. Expression of HMOX-1, a gene encoding a
protein involved in oxidative stress, was also slightly increased with
20 mM TRO.
Activity of the NTCP transporter
The activity of the NTCP transporter was estimated through
measuring sodium-dependent intracellular accumulation of radio-
labelled taurocholate substrate after a 30 min incubation period
with 0.17 mM [3H] taurocholate in the presence or absence of
sodium. In control cultures, NTCP activity in HepaRG cells
represented around 50% of that measured in PHH. NTCP activity
Figure 7. Venn diagram representation of differentially expressed genes in glitazone- and glitazar-treated hepatocytes. Venn
diagrams showed overlap of gene signatures (FC$1.5 and p#0.01) in at least two concentrations of each glitazone and glitazar in PHH (a) and
HepaRG cells (b).
doi:10.1371/journal.pone.0018816.g007
PPARc Target Genes in Human Liver
PLoS ONE | www.plosone.org 10 April 2011 | Volume 6 | Issue 4 | e18816
Table 4. Main target genes regulated by PPAR agonists in primary human hepatocytes and HepaRG cells.
TRO ROSI MURA TESA
Lipid and hormone transport CD36 SLC27A4 CD36 SLC27A4 CD36 SLC27A4 CD36 SLC27A2
SLC27A2
AcylcoA formation hydrolysis
and binding
ACSL5 FABP4 ACSL1 FABP1 ACSL1 FABP1 ACSL1 ACOT12
FABP1 FABP5 ACSL3 FABP3 ACSL3 FABP3 ACSL3 FABP1
FABP3 ACSL5 FABP4 ACSL5 FABP4 ACSL4 FABP3
FABP5 FABP5 ACSL5 FABP4
ACOT1 FABP5
Mitochondrial b-oxidation and
oxidative phosphorylation
CPT1A SLC25A20 ACADL HADHA ACAA2 ETFDH ACAA2 ETFDH
CPT2 TXNIP CPT1A HADHB ACADL HADHA ACADM HADHA
HADHA UCP2 CPT2 SLC25A20 ACADVL HADHB ACADS HADHB
ETFDH TXNIP CPT1A SLC25A20 ACADVL SLC25A20
CPT2 TXNIP CPT1A TXNIP
CRAT UCP2/UCP2 CPT2
Ketogenesis and ketolysis FGF21 HMGCS2 BDH1 HMGCS2 BDH1 HMGCS2 FGF21 HMGCS2
FGF21 FGF21
Peroxisomal b-oxidation ABCD3 ECH1 ABCD2 ABCD2 HACL1 ABCD3 HSD17B4
CROT HACL1 CROT ABCD3 HSD17B4 ACOX1 PEX11A
PEX11A ECH1 PEX11A CROT PEX11A ECH1
Microsomal v hydroxylation CYP4A11 CYP4A11 ALDH3A1 ALDH3A1 CYP4A11 CYP4A11 CYP4X1
CYP4A11 CYP4A11 CYP4X1
Lipogenesis AGPAT6 ELOVL6 AGPAT5 SCD AGPAT5 SCD ACACB
AGPAT6 SLC25A10 ELOVL6 SLC25A10 AGPAT2
HSD17B2 SREBF1 FADS1 MLYCD
Lipase and lipid droplets ADFP PLIN1 ADFP PLIN1 ADFP LIPE ADFP LIPE
CES1 PLIN4 CIDEC PLIN4 CES1 PLIN1 CES1 PLIN1
CIDEC LIPE CIDEC PLIN4 CES3 PLIN4
LIPE G0S2 PNPLA2 CIDEC
Lipoprotein uptake and
metabolism
ANGPTL4 ANGPTL4 LIPC ANGPTL3 LIPC ANGPTL4 APOA5
APOA2 ANGPTL3 LPL/LPL ANGPTL4 LPL APOA1 LPL
VLDLR APOA1 MTTP APOA1 MTTP APOA2 VLDLR
APOA2 PLTP APOA2 PLTP
APOC3 VLDLR APOA5 VLDLR
APOC3
Biotransformation ADH1B CYP2C8 ADH1B CYP2C9 ADH1B CYP3A4 ADH1B CYP2J2
AKR1B1 CYP3A4 AKR1B1 CYP2E1 CYP1A1 CYP3A7 CYP1A1 EPHX2
AKR1B10 CYP3A7 AKR1B10 CYP2J2 CYP1A2 EPHX2 CYP3A4 GSTA3
CYP2B6 MGST3 AKR1C3 CYP3A4 CYP2C8 GSTA3 CYP3A7 MGST3
CYP1A1 CYP3A7 CYP2C9 MGST3
CYP1A2 EPHX2 CYP2E1
CYP2B6 GSTA3
CYP2C8 MGST3
Amino acid metabolism OTC ABAT GPT ABAT GLS2 ABAT CTH
TAT ACMSD HAL ACSMD GPT AGXT2 GLS2
AGXT2 HPD AGXT2 HAL ARG1 OTC
ARG1 OTC ARG1 HPD CBS PAH
CBS PAH CBS OTC TAT
CTH TAT CTH PAH
GLS2 GLS PSAT1
TAT
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was much greatly reduced, decreasing to 70% vs 33% and to 8 2%
vs 60% after treatment with 5 and 20 mM TRO, respectively
(Figure 8). By contrast, the activity remained unchanged with
ROSI and was enhanced 1.5 to 2.0-fold by MURA and TESA in
PHH, while a decreased was noticed following ROSI and MURA
treatment in HepaRG cells.
Discussion
While the effects of PPARa activation on gene regulation in
rodent and human liver have been extensively investigated [16–
18], only a few studies have addressed hepatic gene regulation by
PPARc or PPARa/c and have been restricted to the analysis of a
Table 5. Validation by qPCR analysis of the microarray results in HepaRG cells exposed to PPAR agonists.
Gene name qPCR results Microarray results
TRO
5 mM
TRO
20 mM
ROSI
20 mM
MURA
20 mM
TESA
300 mM
TRO
5 mM
TRO
20 mM
ROSI
20 mM
MURA
20 mM
TESA
300 mM
FABP4 12.9 24.1 45.8 41.2 73.9 6.5 8.0 2.7 13.5 15.7
PDK4 1.1 2.9 9.6 4.7 8.3 1.3 1.7 4.2 1.1 20.0
FABP1 2.2 2.6 2.1 6.1 4.5 1.7 1.4 1.3 2.0 2.8
ADFP 2.6 2.8 2.7 3.8 5.6 2.4 2.9 3.9 1.6 8.6
CYP3A4 2.5 4.1 16.5 3.9 7.9 2.5 3.3 4.4 -1.2 2.9
CYP2B6 1.5 1.9 3.7 -1.1 -1.0 1.3 1.1 1.3 -1.1 1.1
HMOX1 1.4 1.7 -1.1 -1.0 1.3 1.4 1.6 1.8 1.4 3.3
ALB 1.4 0.9 1.3 1.4 1.9 1.0 -1.4 -1.6 -1.0 -1.2
ALD-B -1.3 0.6 -1.4 -1.4 -2.0 -1.2 -1.8 -1.9 -1.1 -2.1
PPARa -1.3 0.7 1.4 1.8 -1.2 1.0 1.0 -1.3 1.1 -1.2
PPARc1 1.9 1.3 -1.1 -1.7 -1.5 -1.1 -1.1 -1.1 1.0 -1.0
mRNA fold change for each gene corresponds to the ratio of mRNA expression in HepaRG cells treated by PPAR agonists for 24h vs their untreated counterparts; the
values are means of at least two microarrays or three qPCR experiments.
doi:10.1371/journal.pone.0018816.t005
TRO ROSI MURA TESA
Inflammation CCL2 CXCL10 APCS MT1A APCS IL1B BIRC3 IL1B
CCL3 IL1B CCL2 ORM2 BIRC3 IL1RAP CRP PLA1A
CRP VNN1 CCL3 PLA1A CCL2 IL8 CCL3 VNN1/VNN1
CD68 SAA4 CCL3 MT1A EMR1
CRP TRAF1 CEBPB ORM2
CXCL10 VCAM1 CRP PLA1A
EMR1 VNN1 CXCL10 SAA4
IL1B
Cholesterol/Bile tansport and
metabolism
ABCB4 SLC10A1 ABCB4 CYP7A1 ABCB11 CYP7A1 ABCB4 CYP27A1
CYP7A1 SLCO1B3 ABCC2 CYP8B1 ABCB4 CYP8B1 ABCB11 SLC10A1
ABCG5 NPC1 ABCG5 EMR1 CAV1 SLC10A2
ABCG8 SLC10A1 ABCG8 NPC1 CYP7A1
CAV1 SLC10A2 CAV1 SLC10A1
CYP27A1 SLCO1B3 CYP27A1 VCAM1
Oxidative stress HMOX1 POR HMOX1 POR HMOX1 POR HMOX1 POR
OASL OASL OASL OASL
Immune system LECT2 MBL2 LECT2 MBL2 LECT2 MBL2 LECT2 MBL2
Miscellanous CD14 KCND2 CD14 KCND2 CD14 KCND2 CD14 KCND2
IRF7 SGK2 CD52 SGK2 CD52 SGK2 CD52 SGK2
IRF7 IRF7 IRF7
Up-regulated genes: in both cell models (capital bold), primary human hepatocytes only (capital) and HepaRG cells only (italic). Down-regulated genes are underlined.
doi:10.1371/journal.pone.0018816.t004
Table 4. Cont.
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small subset of genes [4]. To our knowledge, the present report
describes the first analysis of overall gene expression profiles
induced by PPARc and PPARa/c agonists in human hepatocytes,
using the transcriptomic approach. Although our data highlighted
huge variations in gene expression profiles depending on
hepatocyte donor, the class of PPAR agonist, the specific agonist
and its concentration, they also showed that PPARc and PPARa/
c control a large number of common target genes and allowed the
identification of subsets of genes regulated by only one PPAR
isotype.
Previous studies have shown that the use of high chemical
concentrations result in the deregulation of an increasing numbers
of nonspecific genes, such as those involved in apoptosis/necrosis
and cellular stress [19], thereby supporting the choice to analyse
several chemical concentrations in our study. Our preliminary
toxicity study using a molar comparison ranked TRO . ROSI <
MURA . TESA. In agreement with clinical and experimental
studies, [20,21] TRO was found to be the most cytotoxic
compound, causing a significant decrease in intracellular ATP
content at 40 mM, especially in HepaRG cells. The higher
cytotoxicity associated with ROS production, of TRO compared
to ROSI, in human hepatocytes has been previously reported [22]
and found to be PPARc-independent. This supports the view that
TRO toxicity is a non-receptor mediated effect and is most likely
the result of a primary interaction with mitochondria [23].
Accordingly, 40 mM TRO and 100 mM ROSI used in our study
represented around 8- and 100-fold the therapeutic plasma
concentration, respectively. This could explain the large safety
margin observed with ROSI but not with TRO for hepatotoxicity.
To our knowledge, in vitro hepatotoxicity of glitazars had not
been previously reported. In our study, while ATP loss and ROS
production were observed from 100 mM MURA, no effect was
observed with 300 mM and only a slight ATP decrease was noticed
at 2000 mMTESA. One hundred mMMURA and 300 mMTESA
correspond, respectively, to around a 70-fold and .400-fold
therapeutic plasma concentration [24], which would agree with
the absence of any liver damage reported in patients treated with
these two compounds during clinical trials.
The gene expression profiles obtained within the 4 hepatocyte
donors showed poor overlap. Indeed, similarity was only 0.3 to
14.4% of the total number of the genes deregulated in the 4
populations, whatever the test compound. Only a small subset of
commonly deregulated genes was shared between hepatocytes
from the 4 donors following treatment with low concentrations of
the PPAR agonists. This is in agreement with the findings reported
by Goyak et al., showing that the number of genes modulated in
common in ten human hepatocyte donors treated with arochlor
1254, di(2-ethylhexyl)phthalate or phenobarbital, did not exceed
0.1% of the total deregulated genes [25].
Noteworthy, many genes that were induced only in several
hepatocyte donors, were no longer modulated when the gene
expression profiles of all 4 donors were combined. Thus, whereas
FABP5 and PLIN4 were respectively induced at least 2.0- and 4.7-
fold in two out of four hepatocyte donors after TESA treatment,
their fold change was only 1.4 and 2.3 respectively when the four
individual values were combined. Similarly, anti-correlated genes,
such as PDK4, could not be detected after combining data.
Despite the large variable number of total deregulated genes
and the low percentages of common deregulated genes between
donors by the different compound treatments, some major
metabolic pathways were found to be reproducibly modulated
by both PPARc and dual PPARa/c agonists by Ingenuity
Pathway AnalysisH, especially fatty acid metabolism, LPS/IL1
mediated inhibition of RXR function and xenobiotic metabolism
pathways. Accordingly, many specific genes targeting various lipid
metabolic pathways were modulated by both PPARc and
PPARa/c agonists, in at least several human hepatocyte donors
and for some concentrations (Table S3). Thus, many genes
involved in pharmacological PPAR targeted functions were up-
regulated, including intracellular uptake and binding of fatty acids
Figure 8. NTCP activity in primary human hepatocytes and HepaRG cells after 24 h treatment with PPAR agonists. NTCP activity was
determined at two concentrations of TRO, ROSI, MURA or one concentration of TESA. Each bar chart colour represents a cell condition treatment.
Results are normalized to control cells and expressed as means 6 S.D.of three independent experiments.* p,0.05.
doi:10.1371/journal.pone.0018816.g008
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(SLC27A2, CD36, FABPs, PLIN, CIDEC, ADFP), hepatic
ketogenesis (FGF21, HMGCS, BDH1), mitochondrial b-oxidation
(ACAD, CPT2), peroxisomal b-oxidation (ABCD3, ECH1),
lipogenesis (AGAPTs, SCD), lipolysis (PNPLA2, LIPE), lipoprotein
metabolism (LPL, ANGPTL4) and glucose/glycerol metabolism
(AQP7, GYS2, PDK4, TXNIP). The direction of changes induced
by PPAR agonists was usually similar in both human hepatocytes
and HepaRG cells. However, CYP4A11, the main human CYP of
the CYP4A gene subfamily that catalyzes microsomal v-hydroxyl-
ation of fatty acids was down-regulated in HepaRG cells while it was
up-regulated in human hepatocytes. Also, ALDH3A1 was up-
regulated by ROSI but down-regulated by MURA in human
hepatocytes. Genes involved in other peroxisomal functions, such as
amino acid (TAT, OTC) and cholesterol (CYP7A1, SLC10A1)
metabolisms were negatively affected by all PPAR agonists tested. In
addition, genes related to biotransformation (CYP3A4, MGST3),
inflammation (SAA4, PLA1A), oxidative stress (HMOX1, POR)
and immunity (MBL2, OASL) were found deregulated by both
glitazones and glitazars.
Moreover, various genes previously described as specific
PPARa target genes were found modulated not only by glitazars
but also by glitazones. These genes were involved in numerous
major biological functions such as lipoprotein metabolism (LIPC,
PCTP), inflammation (VNN1), peroxisomal b-oxidation
(PEX11A), and ketogenesis (FGF21). The fact that PPARa and
PPARc agonists can activate the same target genes is not
surprising since both PPARa and PPARc recognize similar
DNA response elements. PPARa target genes have also been
found to be deregulated by PPARc agonists in liver of obese mice,
without concomitant overexpression of PPARc [26].
In addition, in the present study, several specific glitazar target
genes were identified, these being involved in peroxisomal b-
oxidation (ACAA2, ACADVL, ME1), lipoprotein metabolism
(APOA5), lipogenesis (FAD) and inflammation (BIRC3) likely
reflecting the involvement of the PPARa component of these
molecules. By contrast, the up-regulation of the three xenobiotic
metabolism genes AKRIB10, CYP2B6 and CYP2C8 was
restricted to glitazones, in accordance with previous studies
describing CYP2B6 and 3A4 induction by glitazones [27–29].
Noteworthy, it must be borne in mind that, in addition to limited
qualitative differences in the gene sets deregulated by the two
classes of agonists, major quantitative differences between ROSI
and MURA at a 50 mM concentration were sometimes observed,
as, for example, for PDK4, FGF21 and PLIN genes.
Moreover, many fewer genes were specifically modulated by
TRO or TESA compared to ROSI or MURA in both PHH and
HepaRG cells. These differences could be related to the higher
affinity of these two latter compounds for PPARs. Indeed, in
transfected CV-1 cells containing GAL4-PPAR chimeras, on the
basis of EC50 values (i.e. concentrations which exhibited 50%
efficacy) the affinity of MURA and TESA for PPARa was 0.32
and 9.44 mM, respectively, and that of TRO, ROSI, MURA and
TESA for PPARc was 2.24, 0.02, 0.11 or 1.82 mM, respectively
[30–32]. Interestingly, cytotoxicity level and hierarchical clustering
analysis also showed that ROSI was more similar to MURA than
to TRO. These data are compatible with the recent withdrawal of
ROSI from the market due to incidents of cardiotoxicity, as
observed with MURA during clinical trials [33,34].
Furthermore, some genes previously reported to be specifically
deregulated in mouse cells, (e.g. CD36, UCP2, PNPLA2, LIPE
[17]) were also found to be altered in human hepatocytes. Such
discrepancies could be related to different experimental conditions
or the hepatocyte donors. Other genes thought to be Kupffer cell
markers, such as CD68 [35] and CD14 [36], were also found to be
altered in human hepatocytes treated with either PPARc or
PPARa/c agonists. LPL, described as a PPARa target gene
restricted to Kupffer cells [37] was also always overexpressed, as
well as its modulating factors such as APOC3 and ANGPTL4.
Since these genes were also found to be responsive in HepaRG
cells, this fact excluded the possibility of their induction by a few
Kupffer cells contaminating the hepatocyte primary cultures.
Generally, in agreement with previous studies [9,10,19,38,39],
the human hepatoma HepaRG cell line appeared to behave as a
primary human hepatocyte population. Hierarchical clustering
analysis showed that some human hepatocytes populations were
closer to HepaRG cells than other human populations. However,
some differences were observed. Thus, acute-phase genes were
more deregulated in HepaRG cells than in human hepatocytes,
(e.g. IL-1b and CRP).
Induction of cholestasis by TRO has already been commented
upon [40]. In our study, we demonstrated that both glitazars and
glitazones decreased the expression of both CYP7A1 and
SLC10A1 (also called NTCP) which are involved in bile acid
biosynthesis and transport, respectively. Moreover, down-regula-
tion of NTCP has been described as an adaptative response to a
decrease of ongoing intrahepatic cholestasis [41]. The down-
regulation of NTCP expression observed in microarrays was
confirmed at the activity level. NTCP activity was inhibited with
TRO in human hepatocytes, supporting the cholestatic effect of
this compound in vivo, as previously described [42]. Unexpectedly,
following treatment with glitazars, NTCP activity was increased in
human hepatocytes, while it was decreased in HepaRG cells.
Further studies are required to explain such discrepancies.
In summary, this first global analysis of gene regulation by
PPARc and PPARa/c agonists in human hepatocytes shows that
despite major inter-individual variability, a large set of genes
involved in various aspects of lipid metabolism and several other
biological processes, was regulated in common leading to the
conclusion that PPARa/c and PPARc agonists control a large
number of common target genes. Only a small set of genes was
specifically deregulated by glitazones. These data give new insights
into the molecular mechanisms of action of PPARc and PPARa/c
agonists and the large inter-individual and unpredictable response
of patients to these compounds.
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